SIBP-03
SIBP-03 is a specifical anti-HER3 antibody. SIBP-03 binds strongly and specifically to recombinant HER3 protein. SIBP-03 inhibits HER3 activation, as well as the downstream PI3K/AKT signaling pathway. SIBP-03 exhibits anticancer activity against squamous cell carcinoma, non-small cell lung cancer, gastric cancer, and breast cancer. SIBP-03 synergistically enhances the antitumor activity of DS-8201 (HY-138298A) and Cetuximab (HY-P9905).
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All EGFR Isoforms
More
Biological Activity
Description
Isotype
Human IgG2 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
[1]|
HER3 |
In Vitro
SIBP-03 (10-4-104 ng/mL) binds strongly and specifically to recombinant human HER3 protein, while no binding is detected with recombinant human EGFR, HER2 or HER4 proteins[1].
SIBP-03 binds to HER3 on the surface of MC38/HER3 cells with overexpressed HER3, while no detectable binding is observed with HER3-negative MC38 cells[1].
SIBP-03 (0.01-10 μg/mL; 24 h treatment of FaDu/BT-474 cells, with 2 h pre-incubation of cells stimulated by NRG1) effectively inhibits ligand-independent and ligand-dependent HER3 activation, as well as the downstream PI3K/AKT signaling pathway, in FaDu, BT-474, and NRG1-stimulated MCF7 and BT-474 cells[1].
SIBP-03 (0.01-100 μg/mL; 120 h) exerts only weak antiproliferative effects on FaDu, A549, BT-474, SK-BR-3 and NCI-N87 cells, but potently inhibits NRG1-stimulated proliferation of MCF7 cells, with an inhibition rate of 74.8% after treatment at 100 μg/mL[1].
SIBP-03 (10-100 μg/mL; 1 h) does not induce complement-dependent cytotoxicity in FaDu cells or HER3-overexpressing MC38/HER3 cells at concentrations of 10 and 100 μg/mL[1].
SIBP-03 (10-100 μg/mL; 5 h) induces ADCC activity in MC38/HER3 cells overexpressing HER3, but fails to induce such activity in BT-474 cells at concentrations of 10 and 100 μg/mL[1].
SIBP-03 (10-100 μg/mL; 5 h) induces antibody-dependent cellular phagocytosis activity in human breast cancer BT-474 cells and HER3-overexpressing MC38/HER3 cells at concentrations of 10 μg/mL and 100 μg/mL[1].
SIBP-03 (30 μg/mL; 144 h) can synergistically enhance the antiproliferative activity of DS-8201 in SK-BR-3 and MDA-MB-453 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human head and neck squamous cell carcinoma FaDu cells, human non-small cell lung cancer A549 cells, human breast cancer BT-474 cells, human breast cancer SK-BR-3 cells, human gastric cancer NCI-N87 cells, NRG1-stimulated human breast cancer MCF7 cells
-
Concentration:0.01-100 μg/mL
-
Incubation Time:120 h
-
Result:Exhibited weak anti-proliferative effects, with inhibition rates ranging from 10.0% to 32.9% at 100 μg/mL in FaDu, A549, BT-474, SK-BR-3, and NCI-N87 cells.
Induced strong anti-proliferative effects, with 74.8% inhibition at 100 μg/mL in NRG1-stimulated MCF7 cells.
In Vivo
SIBP-03 (6 mg/kg; i.v.) exhibits significant anti-tumor activity in the A549 xenograft mouse model, with a tumor growth inhibition (TGI) rate of 57.5% at the dose of 6 mg/kg[1].
SIBP-03 (20 mg/kg; i.v.) exhibits significant antitumor activity in the NCI-N87 xenograft mouse model, with a tumor growth inhibition (TGI) rate of 50.8% at the dose of 20 mg/kg[1].
Single treatment with SIBP-03 (0.6 mg/kg; i.v.) achieves a TGI of 96% in FaDu xenograft-bearing mice, while combination treatment with Cetuximab (HY-P9905) induces a TGI of 152% and causes tumor regression in 66.7% of treated mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Target
ERBB3/HER3
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
Application
ELISA, FACS, Functional assay
Chemical Information
-
SMILES
[SIBP-03]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Li WJ, et al. SIBP-03, a novel anti-HER3 antibody, exerts antitumor effects and synergizes with EGFR- and HER2-targeted drugs. Acta Pharmacol Sin. 2024;45(4):857-866. [Content Brief]
[2]. Li WJ, et al. HER3 upregulation reduces DS-8201 sensitivity in HER2-positive tumor cells by ATR/CHK1/FoxO1 signaling cascade. Acta Pharmacol Sin. 2026;47(2):481-492. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
SIBP-03 Related Classifications
HY-P991984 Related Classifications
Powered by Bioz
Keywords
- SIBP-03
- SIBP03
- SIBP 03
- EGFR
- PI3K
- Akt
- MC38/HER3 cells
- human tumor xenograft models
- neuregulin
- PI3K/AKT signaling pathway
- HER2-positive tumor cells
- BT-474 human breast cancer cells
- HER3
- antibody-dependent cell-mediated cytotoxicity
- antibody-dependent cellular phagocytosis
- MAPK signaling pathway
- Inhibitor
- inhibitor
- inhibit